Make a Change Today

Call: 888.963.3432
Developed by an M.D.

Developed for Doctors.

Created by doctors for doctors over thirty years ago. Medifast Products and Programs have been recommended by over 20,000 doctors since 1980.

The Medifast 5&1 Plan is clinically proven to be safe and effective.

The Medifast 5&1 Plan is clinically proven to be safe and effective.

Scientifically formulated to be safe, filling and nutritious. After being on the Medifast 5 & 1 Plan just a few days, your body shifts to a mild fat-burning state so you can lose weight quickly while preserving muscle tissue.

Get Your FREE Medifast Recipe E-Book!

Clinical Studies

Science sets the Medifast Weight Control Centers Program and your weight loss success apart from the rest.
Clinical studies prove time and again that the Medifast Weight Control Centers Program works.

Read the research below:

Nutrition Journal

The Johns Hopkins University School of Medicine

The Diabetes Educator

Johns Hopkins Bloomberg School of Public Health

A Clinical Program Evaluation

National Institutes of Health

Medifast Weight Control Centers

What is a Case Study?

Nutrition Journal

Purpose of the Study:

A randomized, controlled trial to compare the Medifast 5 & 1 Plan with a low-calorie, food-based diet based on the USDA Food Guide Pyramid.

Results:

Subjects in the Medifast group initially lost an average of 12.3% of their body weight, while the other group lost an average of 6.9%. In addition to losing more weight, the subjects on the Medifast plan showed superior changes in body composition, losing five times more body fat and increasing their bodies’ proportion of lean muscle mass compared to those on the conventional food-based plan.

Reference:

Davis, et al. “Efficacy of a meal replacement diet plan compared to a food-based diet plan after a period of weight loss and weight maintenance: a randomized controlled trial.” Nutrition Journal, 9:11, 2010.

The Johns Hopkins University School of Medicine

Purpose of the Study:

To retrospectively evaluate the efficacy of a medically supervised, protein-supplemented modified fasting program (Medifast) for weight reduction and to evaluate the impact of weight reduction on coexisting health problems.

Results:

Medically supervised, protein-sparing modified fasts offer a safe and effective means of weight reduction and are accompanied by significant improvements in coexisting health problems. Of samples taken, males lost an average of 67 lbs and females lost an average of 47 lbs during fasting. The study found significant reductions in systolic and diastolic blood pressure, and total cholesterol and triglycerides, as well as the normalizing of blood pressure and hypertensive patients.

Reference:

Crowell, M.D. & Cheskin L.J. The Johns Hopkins University School of Medicine. Multicenter Evaluation of Health Benefits and Weight Loss on the Medifast Weight Management Program.

The Diabetes Educator

Purpose of the Study:

To evaluate the efficacy of the standard ADA (American Diabeties Association) self-selected diet (SD) vs. a portion-controlled diabetic food diet (PCD) in obese patients with NIDDM. The study also evaluated not only the metabolic effects in the long term, but also compliance and any consequent medication changes in patients of the two weight loss regimens (16-34 weeks of active weight loss, 52 weeks of maintenance). The meal replacements (Medifast) used in this study are soy-based products (bars, shakes, soups) that are considerably lower in sugar than their non-diabetic counterparts and other popular diet products on the market.

Results:

Significantly greater results were achieved after the initial 34 weeks of weight loss by participants in the PCD group in pounds and percent weight loss, insulin level and hemoglobin A1c. The PCD group also saw significant improvements within group in BMI, systolic BP, diastolic BP, waist/hip measurements, cholesterol, HDL triglycerides, glucose and percent body fat. Dropout rates were less in the PCD in both weight loss and weight maintenance. During weight loss, participants in the PCD group significantly decreased their use of medications to treat Type 2 DM. Participants in the PCD group also self-reported higher ease of compliance with the diet compared to the SD group (64.2% vs. 56.0%). Researchers recommended that a PCD be considered for type 2 diabetics desiring weight loss, but that periodic use of SD during weight maintenance will not adversely affect weight loss efforts. The research supports that using a portion-controlled diet will produce comparable if not better outcomes in type 2 diabetics attempting to control their weight. The study was published in the 2008 January/February issue of The Diabetes Educator. The peer-reviewed journal is the official journal of the American Association of Diabetes Educators. The study was also presented at American Diabetes Association’s 65th Annual Scientific Session in San Diego, CA, June 11, 2005.

Reference:

Cheskin, MD, FACP; Mitchell, MS; Lewis, BA; Jhaveri, MD Yep, BS. Johns Hopkins University School of Bloomberg Public Health. “Efficacy of 2 Diet Plans Designed for People with Type 2 Diabetes on Weight and Health Measures.” The Diabetes Educator. 2008 January/February.

Johns Hopkins Bloomberg School of Public Health

Purpose of the Study:

To compare the safety and efficacy of supplemental Medifast portion-controlled meal replacements (MRs) with a USDA Food Guide Pyramid-based diet. Both weight loss diets were 20% energy-restricted (~500 kcal deficit). Eighty, 8-15 yo children, BMI>95th%ile, were screened and 40 randomized to either a MR diet (3 MRs/d during active weight loss and 2 MRs/d during maintenance) or to the food-based diet. Subjects were further randomized to dieting alone or with a parent.

Results:

By ITT analysis, dieting with a parent vs. without or food vs MR, made no difference in weight outcome. However, following initial weight loss (6 mos) and 1 yr maintenance (18 mos), significant (p less than or equal to 0.05) benefits were seen in the MR group in BMI%ile (0 mos=98.8 ± 1.0, 6 mos=96.6 ± 3.2, 18 mos=96.4 ± 3.4); body fat (?5.9%@ 6 mos, 5.3% @ 18 mos), total cholesterol (?6.7%, 5.6%), LDL (?19.8%, 7.9%) and triglycerides (?23.6%, 22.3%). No significant between-group differences, differences in growth rates, or adverse events were observed. Conclusions: Among overweight 8-15 yo children, dieting with or without a parent, meal replacements were as safe and effective as a food-based diet for weight loss and maintenance. (Supported by Medifast Inc., MD)

Reference:

Cheskin, Lawrence J.; Davis, Lisa M.; Hanlon-Mitola, Andrea; Mitchell, Amy; Jhaveri,Ami; Mary, Yep; Mitchell, Vanessa. Johns Hopkins Bloomberg School of Public Health, Center for Human Nutrition, Department of International Health, Baltimore, MD 21205. “Efficacy of Parent-Child Dieting Plans Incorporating Medifast Meal Replacements for Weight Loss. RCT Comparing Balanced Energy Deficit Diets With or Without Meal Replacements for Weight Loss and Maintenance Among Children Dieting Alone or With a Parent.”

A Clinical Program Evaluation

Purpose of the Study:

The purpose of the study is to evaluate the long-term impact of Medifast meal-replacement supplements combined with appetite suppressant medication (ASM) among participants who received a minimum of 12-weeks of treatment.

Results:

Participants who completed 52 weeks of treatment experienced substantial weight losses at 12 weeks (-9.4 ± 5.7 kg), 24 weeks (-12.0 ± 8.1 kg), and 52 weeks (12.4 ± 9.2 kg), and all measures were significantly different from baseline weight (0.001 for all contrasts) for both true completers (n=34) and for ITT analysis (n=1,351). Fifty percent of patients remained in the program at 24 weeks and nearly 25% were still participating after one year. This weight-loss program using a combination of MMRS and ASM produced significant and sustained weight losses at 52 weeks. Results are better than those typically reported for obesity pharmacotheraphy in both short- and long-term studies, and are also better than those reported for partial meal-replacement programs. Program retention at one year was similar to that reported in many controlled drug trials and better than most commercial programs reported in the study.

Reference:

Haddock, C.K.; Poston, W.S.C.; Foreyt, J.P.; DiBartolomeo, J.J.; and Warner, P.O. “Effectiveness of Medifast Supplements Combined with Obesity Pharmacotherapy: A Clinical Program Evaluation.”

National Institutes of Health

Purpose of the Study:

To examine whether women on a weight loss program who are carriers of a genetic variant (Trp64Arg) lose less visceral fat than women who do not have this gene. Participants entered a medically supervised weight loss program aimed at reducing body weight to less than 120% of ideal value. Food was self selected with dietitian supervision, with or without the inclusion of TakeShapeTM, a Medifast brand modified fasting supplement.

Results:

Reductions in body weight, BMI, total fat mass and fat-free mass were not significantly different between carriers and non-carriers of the variant. Both groups experienced weight reduction of 31-36.1 pounds, which the study identified as a significant weight-loss effect.

Reference:

National Institutes of Health. “Impaired Capacity to Lose Visceral Adipose Tissue During Weight Reduction in Obese Postmenopausal Women With the Trp64Arg B3- Adrenoceptor Gene Variant.”

Medifast Weight Control Centers

Purpose of the Study:

Coleman, C., Kiel, J., Davis, L.M., Mitola, A., Sonzone, C., (2012) Use of the Medifast meal replacement program for weight loss in overweight and obese clients: A retrospective chart review of three Medifast Weight Control Centers (MWCC). FASEB J. 26, lb327

Results:

Medifast’s meal replacement plan, along with the support and accountability available in the Medifast Weight Control Centers, is an efficacious model that promotes significant weight loss and improvements in body composition.

Reference:

Coleman, C., Kiel, J., Davis, L.M., Mitola, A., Sonzone, C., (2012) Use of the Medifast meal replacement program for weight loss in overweight and obese clients: A retrospective chart review of three Medifast Weight Control Centers (MWCC). FASEB J. 26, lb327

What is a Case Study?

Purpose of the Study:

A chart review was performed to evaluate the association between compliance and the effectiveness of the Medifast meal replacement plan (MD) on body weight from baseline to final weight-loss visit (FV) at three Medifast Weight Control Centers (MWCC) for the years 2007-10.

Results:

Taken together, these results reveal significant associations between several components of compliance and weight loss, but particularly highlight the importance of attendance at weekly visits, a benefit of the Medifast Weight Control Centers model over non-clinic based models.

Reference:

Kiel, J., Coleman, C., Mitola, A., Sonzone, C., Davis, L.M., (2012) The impact of compliance on the effectiveness of the Medifast meal replacement program for weight loss in overweight and obese clients: A retrospective chart review of three Medifast Weight Control Centers (MWCC). FASEB J. 26, lb398.

“The Medifast Center Program is the only one that I recommend.”

Dr. Sherry L. Franklin

A Letter From The Doctor>

Other weight loss plans can say they’re safe and effective, but Medifast California is backed by science!

Find a Medifast California Location Near You!

Call us Today: 888.963.3432
Logo Header Menu